Ascidian and Lilly Enter Global Research Collaboration to Develop RNA Exon Editors for Devastating Kidney Diseases

PartnershipRNA Exon EditorsPositive

AI Analysis

Summary

Ascidian Therapeutics and Eli Lilly announced a global research collaboration combining Ascidian's RNA exon editing platform with Lilly's genetic medicines expertise to develop treatments for inherited kidney diseases.

Outcome Details

Global research collaboration announced for development of RNA exon editors targeting undisclosed inherited kidney diseases; Lilly has option to expand to additional targets

Importance:6/10

Sentiment:

0.60

RNA editinggenetic medicineskidney diseasecollaborationpartnership

Related Companies

$LLY

Read the original article

Published by PR Newswire Biotech on June 3, 2026 11:00 AM

Read Original